Last reviewed · How we verify
NCT05402852
Effectiveness and Safety of EuBone® Capsules for Bone Health in Postmenopausal Women
Phase 4 trial testing EuBone ® capsule in Osteoporosis, Postmenopausal in 30 participants. Status unknown.
31 October 2022
Quick facts
| Lead sponsor | Shandong University |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 June 2022 |
| Primary completion | 31 October 2022 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- EuBone ® capsule — full drug profile →
- placebo
Conditions studied
- Osteoporosis, Postmenopausal — all drugs for Osteoporosis, Postmenopausal →
Sponsor
Shandong University
Who can join
Adults 45 to 75, female only, with Osteoporosis, Postmenopausal. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
EuBone is prepared by mixing eucommia ulmoides extract, fructus ulmoides extract and dodder extract in proportion. The aim of this study is to evaluate the effectiveness and safety of EuBone® capsules in slowing bone loss, preventing bone loss, and improving quality of life compared with placebo in Postmenopausal women.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05402852
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Osteoporosis, Postmenopausal
Currently open trials in the same condition.
- NCT07242612 — Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis · NA · recruiting
- NCT06558188 — Combined Anabolic Therapy · Phase 4 · recruiting
- NCT06655701 — Stress Urinary Incontinence and Sarcopenia in Postmenopausal Osteoporosis · recruiting
- NCT06525688 — New Biomarkers and Therapeutic Targets in Osteoporosis Via Omics Technologies · recruiting
- NCT05655013 — Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2) · Phase 4 · active not recruiting
Other Shandong University trials
Trials by the same sponsor.
- NCT07288346 — Effect of Predictive Model on Double-Balloon Enteroscopy · NA · recruiting
- NCT07325344 — Active Locomotion of Magnetically Controlled Capsule Endoscopy in the Small Bowel: A Feasibility Study · NA · recruiting
- NCT07319312 — Evaluating the Effect of Nurse-Led Stroke Transitional Care in Tanzania · recruiting
- NCT07391787 — Low-acid Contrast Media for Preventing Post ERCP Pancreatitis · completed
- NCT07066059 — Study on the Efficacy and Safety of Shouhui Tongbian Capsules in Protecting Intestine During the Perioperative Period · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05402852 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shandong University
- Last refreshed: 2 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05402852.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing